hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06268132, orgStudyIdInfo id: MLS90, briefTitle: Longevity in Russia, statusModule overallStatus: RECRUITING, startDateStruct date: 2019-12-25, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Center for Strategic Planning, of the Federal Medical and Biological Agency, class: OTHER, collaborators name: Pirogov Russian National Research Medical University, descriptionModule briefSummary: This is an observational cohort study of long-living adults (participants aged 90 and above) from the Central Federal District of Russia.The study seeks to determine the genetic and cellular and molecular determinants of healthy longevity and to assess the impact of lifestyle and socioeconomic and environmental factors on healthy longevity.The study is expected to result in the development of a panel of markers of healthy longevity and/or a model of healthy aging based on the analysis of all factors under consideration., conditionsModule conditions: LONGEVITY 1, conditions: Frailty, conditions: Aging, conditions: Age-related Cognitive Decline, conditions: Aging Disorder, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 4000, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Mortality among long-living adults, primaryOutcomes measure: Morbidity among long-living adults, secondaryOutcomes measure: Aging phenotypes, secondaryOutcomes measure: Social, economic, and medical- history-related determinants, secondaryOutcomes measure: Genetic determinants, secondaryOutcomes measure: Epigenetic determinants, secondaryOutcomes measure: Metagenomic determinants, eligibilityModule sex: ALL, minimumAge: 90 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: RUSSIAN CLINICAL AND RESEARCH CENTER OF GERONTOLOGY, Pirogov Russian National Research Medical University of the Ministry of Healthcare of the Russian Federation, status: RECRUITING, city: Moscow, zip: 129226, country: Russian Federation, contacts name: Irina D. Strazhesko, M.D., Ph.D, role: CONTACT, phone: +7 (499) 187-64-67, email: Istrazhesko@gmail.com, geoPoint lat: 55.75222, lon: 37.61556, hasResults: False
protocolSection identificationModule nctId: NCT06268119, orgStudyIdInfo id: MustafaKU-SBF-GKS-01, briefTitle: Effectiveness of Delirium Care Protocol After Cardiac Surgery, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-03-06, primaryCompletionDateStruct date: 2023-05-15, completionDateStruct date: 2023-05-22, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Gonul Kara Soylemez, class: OTHER, descriptionModule briefSummary: This study was conducted as a quasi-experimental study to determine the effectiveness of the postoperative delirium prevention, diagnosis and intervention protocol in patients monitored in the intensive care unit after cardiac surgery., conditionsModule conditions: Delirium, Postoperative, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The control group received standard care. The intervention group received care in line with postoperative delirium prevention, diagnosis, and intervention., primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 64, type: ACTUAL, armsInterventionsModule interventions name: training nurses and caring for patients to prevent, diagnose, and intervene in postoperative delirium., outcomesModule primaryOutcomes measure: Confusion Assessment Scale in the Intensive Care Unit (CAM-ICU), secondaryOutcomes measure: Glasgow Coma Scale (GCS), secondaryOutcomes measure: Richmond Agitation-Sedation Scale (RASS), secondaryOutcomes measure: Information Assessment Form for Postoperative Delirium (Pretest-Posttest), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Antalya Training and Research Hospital, city: Antalya, state: Center, zip: 07000, country: Turkey, geoPoint lat: 36.90812, lon: 30.69556, hasResults: False
protocolSection identificationModule nctId: NCT06268106, orgStudyIdInfo id: IRB N/A, briefTitle: Graphic Novel for Patients Undergoing EUS-FNB, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-07-30, completionDateStruct date: 2024-08-01, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: The Mediterranean Institute for Transplantation and Advanced Specialized Therapies, class: OTHER, descriptionModule briefSummary: Endoscopy with endoscopic ultrasound (EUS) is a primary technique for diagnosing and treating severe pancreatic disorders. However, the procedure can cause fear and anxiety in patients, especially when a biopsy is involved. Graphic medicine, a form of visual storytelling that explores narratives of healthcare, is being used to alleviate this anxiety.This is a prospective single-center interventional pilot study with the aim to evaluate the impact of a novel graphic on the stress and behaviors of patients with pancreatic lesions undergoing EUS-FNB. The study will run for six months with the aim to enroll patients to llok for differences in the anxiety and stress levels.Enrolled patients will be randomly allocated to the test or control group, with the test group receiving a graphic novel to read while waiting for the procedure. Post-procedure, patients will complete the Beck Anxiety Inventory (BAI) and a modified version of the Depression Anxiety Stress Scales-21 (mDASS-21), now named mASS-14 (modified Anxiety Stress Scales-14), to assess anxiety and stress levels.This study is conducted according to the principles of the Declaration of Helsinki regarding experimentation involving human subjects, and written informed consent will be obtained from all participants before enrollment., conditionsModule conditions: Anxiety, conditions: Pancreatic Cancer, conditions: Pancreatic Cystic Lesions, conditions: Stress, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Graphic novel will be visualized by interventional group before EUS-FNB, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: SINGLE, whoMasked: CARE_PROVIDER, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Graphic novel visualization, outcomesModule primaryOutcomes measure: Anxiety and stress level according to BAI, primaryOutcomes measure: Anxiety and stress level according to mASS-14, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Irccs - Ismett, city: Palermo, state: PA, zip: 90127, country: Italy, contacts name: Giacomo Emanuele Maria Rizzo, MD, role: CONTACT, phoneExt: +393406602502, email: g.rizzo.gr@gmail.com, contacts name: Ilaria Tarantino, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Giacomo Emanuele Maria Rizzo, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Mario Traina, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 38.13205, lon: 13.33561, hasResults: False
protocolSection identificationModule nctId: NCT06268093, orgStudyIdInfo id: XWTETS, briefTitle: The Therapeutic Effect of Thalidomide in Syringomyelia, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2027-02, completionDateStruct date: 2028-02, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Xuanwu Hospital, Beijing, class: OTHER, descriptionModule briefSummary: Purpose: This phase II clinical trial aims to evaluate the indications, therapeutic effects and side effects of thalidomide in refractory syringomyelia.Primary outcome measure: The primary endpoint is the change of ASIA at week 12. The clinical efficacy is defined as ASIA increase ≥ 1 at week 12, as compared with that before thalidomide usage., conditionsModule conditions: Syringomyelia, conditions: Thalidomide, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Thalidomide, outcomesModule primaryOutcomes measure: ASIA Score, secondaryOutcomes measure: syringomyelia remission, secondaryOutcomes measure: The evoked electromyographic signal (eEMG) potential, secondaryOutcomes measure: Visual Analog Scale (VAS), secondaryOutcomes measure: Klekamp and Sammi syringomyelia scale, secondaryOutcomes measure: modified Japanese Orthopaedic Association Scores (mJOA), secondaryOutcomes measure: xuanwu syringomyelia scale, secondaryOutcomes measure: Incidence of complications, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fengzeng Jian, status: RECRUITING, city: Beijing, state: Beijing City, zip: 100032, country: China, contacts name: fengzeng jian, md, role: CONTACT, email: jianfengzeng@xwh.ccmu.edu.cn, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06268067, orgStudyIdInfo id: Renal uptake at F18 FDG PET/CT, briefTitle: Kidney Uptake at F-18 FDG PET/CT Studies and Renal Function Status, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-04-01, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Searching for a possible correlation between renal uptake at F-18-FDG PET/CT and renal functional parameters in both normal subjects and patients with CKD., conditionsModule conditions: Renal Uptake at F-18-FDG PET/CT, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 97, type: ESTIMATED, armsInterventionsModule interventions name: PET/CT, outcomesModule primaryOutcomes measure: significance of renal uptake at F18-FDG PET CT studies, secondaryOutcomes measure: Early detection of patients with CKD, eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06268054, orgStudyIdInfo id: DEH113-III-0123, briefTitle: Efficacy and Safety of DEH113 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea, acronym: LIBERTÀ, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2025-02, primaryCompletionDateStruct date: 2027-02, completionDateStruct date: 2027-09, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: EMS, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study if to evaluate the efficacy and safety of DEH113 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea., conditionsModule conditions: Primary Dysmenorrhea, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 78, type: ESTIMATED, armsInterventionsModule interventions name: DEH113, interventions name: Placebo Comparator, outcomesModule primaryOutcomes measure: Sum of Total Pain Relief (TOTPAR) over 0-6 hours post-dose, secondaryOutcomes measure: Sum of Total Pain Relief (TOTPAR) over 0-4 and 0-8 hours post-dose, secondaryOutcomes measure: Sum of Pain Intensity Difference (SPID) over 4, 6 and 8 hours post-dose., secondaryOutcomes measure: Use of rescue medication, secondaryOutcomes measure: Number of additional drug intake, secondaryOutcomes measure: Patients' Global Impression of Change (PGIC), secondaryOutcomes measure: Incidence of Adverse Events Associated with DEH113 in the Treatment of Primary Dysmenorrhea, eligibilityModule sex: FEMALE, minimumAge: 16 Years, maximumAge: 35 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06268041, orgStudyIdInfo id: 427659, secondaryIdInfos id: R01HD093694, type: NIH, link: https://reporter.nih.gov/quickSearch/R01HD093694, briefTitle: HIT-Stroke Trial 2, acronym: HST2, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-09, primaryCompletionDateStruct date: 2028-01, completionDateStruct date: 2028-04, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: University of Cincinnati, class: OTHER, collaborators name: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), collaborators name: University of Kansas Medical Center, collaborators name: University of Delaware, descriptionModule briefSummary: People who had a stroke at least 6 months prior and who still have difficulty with walking will each be randomly assigned to receive either moderate or vigorous intensity walking exercise. Both protocols will be performed individually with a physical therapist for 45 minutes, 3x/week for 12 weeks. Measures including walking function will be assessed at baseline (PRE), after 4, 8 and 12 weeks of training (12WK) and at 3-month follow up (3moPOST), by raters who are unaware of the participant randomization., conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 156, type: ESTIMATED, armsInterventionsModule interventions name: Moderate-Intensity Aerobic Training, interventions name: High-Intensity Interval Training, outcomesModule primaryOutcomes measure: 6-Minute Walk Test Distance, secondaryOutcomes measure: 6-Minute Walk Test Distance, secondaryOutcomes measure: Self-Selected Gait Speed, secondaryOutcomes measure: Fastest Gait Speed, secondaryOutcomes measure: PROMIS-Fatigue Scale version 8a, secondaryOutcomes measure: Aerobic Capacity, secondaryOutcomes measure: EuroQol-5D-5L, eligibilityModule sex: ALL, minimumAge: 30 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Delaware, status: RECRUITING, city: Newark, state: Delaware, zip: 19713, country: United States, contacts name: Jane Diehl, role: CONTACT, email: strokestudies@udel.edu, contacts name: Darcy Reisman, PT, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.68372, lon: -75.74966, locations facility: University of Kansas Medical Center, status: RECRUITING, city: Kansas City, state: Kansas, zip: 66160, country: United States, contacts name: Sasha Moores, role: CONTACT, phone: 913-588-2697, email: reachlab@kumc.edu, contacts name: Sandra Billinger, PT, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.11417, lon: -94.62746, hasResults: False
protocolSection identificationModule nctId: NCT06268028, orgStudyIdInfo id: BELMA TA, briefTitle: Discharge Training Given to Primiparous Mothers Who Had a Cesarean Delivery, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-01-10, primaryCompletionDateStruct date: 2024-06-10, completionDateStruct date: 2024-11-10, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Aydin Adnan Menderes University, class: OTHER, descriptionModule briefSummary: This study aimed to determine the effect of discharge training given to primiparous mothers who gave birth by cesarean section on the level of readiness for discharge.The research is a pre-test-post-test, randomized controlled experimental study., conditionsModule conditions: Education, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: Training, outcomesModule primaryOutcomes measure: A pre-test will be applied to 70 women who constitute the sample of the research., secondaryOutcomes measure: Apost-test will be applied to 70 women who constitute the sample of the research., eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Aydın Maternity and Child Health Hospital, city: Aydın, zip: 09010, country: Turkey, geoPoint lat: 37.84501, lon: 27.83963, hasResults: False
protocolSection identificationModule nctId: NCT06268015, orgStudyIdInfo id: Pro00115311, briefTitle: Botensilimab and Balstilimab Optimization in Colorectal Cancer, acronym: BBOpCo, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2028-07, completionDateStruct date: 2028-07, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Nicholas DeVito, MD, class: OTHER, collaborators name: Gateway for Cancer Research, collaborators name: Agenus Inc., descriptionModule briefSummary: This is a single-arm, interventional, pilot clinical trial. Fifteen evaluable patients will have tumor-informed ctDNA testing at baseline and start botensilimab and balstilimab treatment. They will receive botensilimab and balstilimab in 6-week cycles until progression, after which mFOLFOX6 and bevacizumab or panitumumab will be added to the regimen. Subjects will have safety testing at baseline and every two weeks while on study drug. Study treatment with botensilimab and balstilimab, mFOLFOX6, and bevacizumab or panitumumab will be continued until radiographic or clinical progression, toxicity, or patient withdrawal. Subjects will have one safety follow up visit 30 days after the last treatment and will be followed for survival every 12 weeks for up to 2 years., conditionsModule conditions: Colorectal Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: Botensilimab, interventions name: Balstilimab, interventions name: Oxaliplatin, interventions name: Leucovorin, interventions name: Fluorouracil, interventions name: Bevacizumab, interventions name: Panitumumab, outcomesModule primaryOutcomes measure: Disease control rate based on iRECIST at second restaging scan, primaryOutcomes measure: Proportion of subjects with a best overall response of complete response or partial response according to iRECIST, secondaryOutcomes measure: Disease control rate based on RECIST v1.1 at second restaging scan, secondaryOutcomes measure: Proportion of subjects with a best overall response of complete response or partial response according to RECIST v1.1, secondaryOutcomes measure: Months of overall survival, secondaryOutcomes measure: Months of progression-free survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Duke University, city: Durham, state: North Carolina, zip: 27710, country: United States, contacts name: Nicholas C. DeVito, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 35.99403, lon: -78.89862, hasResults: False
protocolSection identificationModule nctId: NCT06268002, orgStudyIdInfo id: 5876557033, briefTitle: Effect of Vernonia Cinerea Lozenges as a Smoking Cessation Aid in Patients With Non-communicable Diseases, statusModule overallStatus: COMPLETED, startDateStruct date: 2017-09-01, primaryCompletionDateStruct date: 2021-09-30, completionDateStruct date: 2021-12-31, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Chulalongkorn University, class: OTHER, descriptionModule briefSummary: Vernonia cinerea is an herbal which has been recorded in many Thai herbal formulation and Thai traditional medicine has used this herbal for treating various diseases included hypertension, asthma, fever, hepatitis, kidney stone and smoking cessation. Now aday there are more interest for using Vernonia cinerea as a medication to aid smoker to quit smoking because it is cheaper than other current therapeutic medications. The objective of this study is to evaluate efficacy and safety of Vernonia cinerea lozenge for smoking cessation when compared to placebo., conditionsModule conditions: Smoking Cessation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This study was a multicenter randomized, paralleled, double-blind, controlled trial at 5 hospitals and 2 community pharmacies in Thailand, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 93, type: ACTUAL, armsInterventionsModule interventions name: Vernonia cinerea, interventions name: Placebo, outcomesModule primaryOutcomes measure: continuous abstinence rate, secondaryOutcomes measure: continuous abstinence rate (CAR) and point prevalence rate, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Krittin Bunditanukul, city: Bangkok, zip: 10600, country: Thailand, geoPoint lat: 13.75398, lon: 100.50144, hasResults: False
protocolSection identificationModule nctId: NCT06267976, orgStudyIdInfo id: REB23-1003, briefTitle: Validation of the ProSomnus® RPMO2 Device, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-10, primaryCompletionDateStruct date: 2024-05-31, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: ProSomnus Sleep Technologies, class: INDUSTRY, descriptionModule briefSummary: The purpose of the study is to:1. Evaluate the SpO2 accuracy of the oximeter component of the ProSomnus RPMO2 Device during non-motion conditions over the range of 70-100% SaO2 by comparison to SaO2 values determined by arterial blood sample specimen analyzed by a CO-oximeter.2. Evaluate the pulse rate performance simultaneously collected over the SpO2 range., conditionsModule conditions: Healthy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: ProSomnus RPMO2, outcomesModule primaryOutcomes measure: SpO2 accuracy, primaryOutcomes measure: Pulse rate accuracy, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: University of Calgary, city: Calgary, state: Alberta, zip: T2N4N1, country: Canada, contacts name: Brad Hansen, role: CONTACT, phone: 403-210-8925, email: bhanse@ucalgary.ca, geoPoint lat: 51.05011, lon: -114.08529, hasResults: False